Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
A phase 2 trial of Resminostat in Hodgkin lymphoma, run by 4SC AG, completed.
Overview
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT01037478 by 4SC AG, with 37 participants recorded, started 2009-12 and reaching its primary completion in 2012-01. Interventions recorded: Resminostat (4SC-201). Conditions recorded: Hodgkin's Lymphoma.
Linked to the drug Resminostat because the registry names it among its interventions and Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- Trial4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
Shares 4SC, Resminostat and the tag pipeline.
- TrialResminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
Shares 4SC, Resminostat and the tag pipeline.
- TrialA Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Shares Hodgkin lymphoma and the tag pipeline.
- TrialT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Shares Hodgkin lymphoma and the tag pipeline.
- TrialPhase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
Shares Hodgkin lymphoma and the tag pipeline.
- TreatmentEnglumafusp alfa
Shares Hodgkin lymphoma and the tag pipeline.
- TrialA First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Shares Hodgkin lymphoma and the tag pipeline.
- TreatmentCD19 t-haNK
Shares Hodgkin lymphoma and the tag pipeline.